Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 1

Conditions

Hematologic Neoplasms 2Neutropenia 1Neoplasms 1Febrile Neutropenia 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Meropenem × 90 days × Clear all
NCT07590648 2026-05-15

E-STOP2

Hospital Universitari Vall d'Hebron Research Institute

Phase 4 Not yet recruiting
136 enrolled
Classical hematologyOther hematologic neoplasm

Neoplasms, Neutropenia, Hematologic Neoplasms, Febrile Neutropenia

NCT04983901 2026-04-06

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 38 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡